August 13, 2020 ENZYCHEM LIFESCIENCES ANNOUNCES FDA ACCEPTANCE OF PHASE 2 STUDY OF EC-18 IN PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) DUE TO COVID-19 PNEUMONIA Explore further
August 13, 2020 FDA accepts Enzychem’s Phase 2 study for COVID-19 treatment candidate Explore further
August 6, 2020 S. Korean bio firm wins FDA approval for clinical trials of coronavirus treatment Explore further
